AbCellera Biologics (ABCL) Debt to Equity: 2020-2025
Historic Debt to Equity for AbCellera Biologics (ABCL) over the last 4 years, with Mar 2025 value amounting to $0.01.
- AbCellera Biologics' Debt to Equity fell 81.16% to $0.01 in Q1 2025 from the same period last year, while for Mar 2025 it was $0.01, marking a year-over-year decrease of 81.16%. This contributed to the annual value of $0.01 for FY2024, which is 82.52% down from last year.
- Latest data reveals that AbCellera Biologics reported Debt to Equity of $0.01 as of Q1 2025, which was up 11.97% from $0.01 recorded in Q4 2024.
- Over the past 5 years, AbCellera Biologics' Debt to Equity peaked at $0.05 during Q2 2023, and registered a low of $0.01 during Q4 2024.
- Moreover, its 3-year median value for Debt to Equity was $0.04 (2023), whereas its average is $0.03.
- Its Debt to Equity has fluctuated over the past 5 years, first soared by 136.16% in 2022, then plummeted by 82.52% in 2024.
- AbCellera Biologics' Debt to Equity (Quarterly) stood at $0.02 in 2021, then skyrocketed by 60.33% to $0.04 in 2022, then climbed by 22.19% to $0.04 in 2023, then plummeted by 82.52% to $0.01 in 2024, then plummeted by 81.16% to $0.01 in 2025.
- Its Debt to Equity stands at $0.01 for Q1 2025, versus $0.01 for Q4 2024 and $0.02 for Q3 2024.